ClinicalTrials.gg
CompletedNCT05379829Updated Dec 31, 2025

A Research Study of How the Medicine Ziltivekimab Works in the Body of Chinese Men and Women With Kidney Disease and Inflammation

A Phase 1 interventional study of Ziltivekimab and Placebo in Chronic Kidney Disease and Systemic Inflammation, sponsored by Novo Nordisk A/S. Completed at 7 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-31.

Sponsored by Novo Nordisk A/S · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Jun 2024, 2 years 5 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 29 studies in Renal Insufficiency, Chronic by Novo Nordisk A/S — 5 open to participants now, 6 under way, 1 of them phase 3. Renal Insufficiency, Chronic · Novo Nordisk A/S.

Enrollment
16th of 18
24 · median 128
Started
2022
the only one that year
Phase 1
5 of 29
1 open now
Registered
15th of 29
by date

Among the 29 studies in Renal Insufficiency, Chronic by Novo Nordisk A/S, this one is the 16th largest by enrollment of the 18 interventional ones that give a count, is the only one that started in 2022, is one of 5 in phase 1, and was the 15th registered.

Renal Insufficiency, Chronic

3,096 studies on the registry are indexed under Renal Insufficiency, Chronic; 701 are open to participants now.

Browse Renal Insufficiency, Chronic studies →

Open to participants now

5 of the 29 studies in Renal Insufficiency, Chronic by Novo Nordisk A/S are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Who these studies take

Of the 434 Renal Insufficiency, Chronic studies recruiting now, 244 (56%) set no upper age limit and 110 (25%) stop at 75 or younger; 44 take children under 18; 80 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 29 studies in Renal Insufficiency, Chronic by Novo Nordisk A/S, or all of them as a file.
02

Study summary

This study is conducted to see how the ziltivekimab works in the body of Chinese people with chronic kidney disease and systemic inflammation. Participants will either get ziltivekimab (active medicine) or placebo (a dummy medicine which has no effect on the body. Participants' chance of getting ziltivekimab or placebo is the same.

Participants will get their study medicine in a pre-filled syringe. The study doctor or staff will do 3 injections of study medicine during clinical visits.

The study is expected to last for about 6 months. Participants will have blood and urine samples taken at all of the clinic visits. Participants will have their heart examined using electrodes (electrocardiogram).

Women cannot take part if pregnant, breast-feeding or planning to get pregnant during the study period.

03

Conditions studied

  • Chronic Kidney Disease and Systemic Inflammation
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Estimated (eGFR) greater than or equal 15 and less than 60 mL/min/1.73 m\^2 [Millilitre/minute] (using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) creatinine equation)
  2. Serum high-sensitivity C-reactive protein (hs-CRP) greater than or equal to 2 mg/L [Milligram Per Litre] at screening (visit 1).

Exclusion criteria

Exclusion criteria:

Laboratory values

  1. less than 2×10\^9/Litre at screening (visit 1).
  2. count less than 120×10\^9/Litre at screening (visit 1).
  3. (ALT) or aspartate aminotransferase (AST) greater than 2.5 × at screening (visit 1).

Medical conditions

  1. Clinical evidence of, or suspicion of, active infection at the discretion of the investigator.
  2. History of gastrointestinal perforation. (Note: History of perforated appendicitis more than 5 years prior to screening (visit 1) is not exclusionary).
  3. History of active diverticulitis in the 5 years prior to randomization (visit 2).
  4. History of inflammatory bowel disease that has been clinically active during the 12 months prior to randomization (visit 2).
  5. Myocardial infarction, stroke, hospitalization for unstable angina pectoris, or within 60 days prior to randomization (visit 2).
  6. Planned coronary, carotid or peripheral artery revascularization known on the day of screening (visit 1).
  7. Major cardiac surgical, non-cardiac surgical, or major endoscopic procedure (thoracoscopic or laparoscopic) within the past 60 days prior to randomization (visit 2) or any major surgical procedure planned at the time of randomization (visit 2). Prior or current medication

1. Use of preventive systemic antibiotics, systemic antivirals, or systemic antifungals at screening (visit 1). (Note: "Systemic" is defined as oral or intravenous (i.v.) administered drugs that are absorbed into the circulation).

2. Use of systemic drugs (both small molecules and biologics) or biologic disease modifying anti-rheumatic drugs (DMARDs including both biologic DMARDs like anti-TNF-alpha and conventional DMARDs like methotrexate) at screening (visit 1) or anticipated chronic use of such drugs any time during the study. (Note: Use of otic, ophthalmic, inhaled, and topical or local corticosteroid injections are not exclusionary).

Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    Ziltivekimab 15 mg

    Participants will receive ziltivekimab at weeks 0, 4 and 8.

    Drug: Ziltivekimab

  • Placebo comparator
    Placebo

    Participants will receive placebo at weeks 0, 4 and 8.

    Drug: Placebo

Interventions

  • Participants will be administered 3 doses subcutaneously (s.c.) every four weeks (Q4W).

  • DrugPlacebo

    Participants will be administered 3 doses s.c. Q4W.

06

What researchers measure

Primary outcomes

  1. Area under the ziltivekimab plasma concentration-time curve in a 4-week dosing interval, multiple doses [MD] (AUCτ,MD)

    Nanograms per millilitre\*days (ng/mL\*days)

    Time frame: During 3rd dosing interval (week 8 to week 12)

Secondary outcomes

  1. Change in hs-CRP (high-sensitivity C-reactive protein

    Milligrams per millilitre (mg/L)

    Time frame: From baseline (week 0) to end of treatment (week 12)

  2. Area under the ziltivekimab plasma concentration-time curve in a 4-week dosing interval, single dose [SD]

    ng/mL\*days

    Time frame: During 1st dosing interval (day 0 to week 4)

  3. Maximum plasma concentration of ziltivekimab after 3rd dose (Cmax,MD)

    ng/mL

    Time frame: After last dose (week 8) to end of study (week 20)

  4. Elimination half-life (t½)

    Days

    Time frame: After last dose (week 8) to end of study (week 20)

07

Study locations

7 sites
  • Peking University Third Hospital
    Beijing, Beijing Municipality 100191, China
  • Beijing Hospital
    Beijing, Beijing Municipality 100730, China
  • Chinses People's Liberation Army General Hospital-Nephrology
    Beijing, Beijing Municipality 100853, China
  • Zhongda Hospital Southeast University-Nephrology
    Nanjing, Jiangsu 210009, China
  • Zhongda Hospital Southeast University-Neurology
    Nanjing, Jiangsu 210009, China
  • The First Affiliated Hospital of Soochow University-Endocrinology
    Suzhou, Jiangsu 215006, China
  • The First Affiliated Hospital Of Soochow University
    Suzhou, Jiangsu 215006, China
08

References and documents

Individual participant data

Plan to share: Yes — According to the Novo Nordisk disclosure commitment on novonordisk-trials.com

Data sharing details ↗ · novonordisk-trials.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2022 to primary completion in Jun 2024, 24 months.

Of 77 industry-sponsored phase 1 interventional studies under Renal Insufficiency, Chronic, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 16. This study's 24 months is above that.

Counting every sponsor, half of 109 studies reached it within 12 months; a quarter within 5 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
May 15, 2022
First posted
May 18, 2022
StartActual
May 30, 2022
Primary completionActual
Jun 12, 2024
CompletionActual
Sep 2, 2024
Last update
Dec 31, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 31, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05379829
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
May 18, 2022
Start date
May 30, 2022
Primary completion
Jun 12, 2024
Completion
Sep 2, 2024
Last update
Dec 31, 2025

Study contacts

Clinical Transparency (dept. 2834)
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ziltivekimab

Start the discussion